Decursin possesses the potential to alleviate transforming growth factor (TGF)-β-induced hepatic stellate cells (HSCs) activation. However, the mechanisms by which decursin alleviates hepatic fibrosis remain not fully understood. Our aim is to explore the function of decursin on regulating HSCs activation and hepatic fibrosis. The anti-fibrotic effect of decursin was evaluated by Masson and Sirius red staining, and immunohistochemical (IHC) and quantitative real-time PCR (qRT-PCR) analysis for alpha-smooth muscle actin (α-SMA) and collagen types I (Col1a1) expression. Ferroptosis was assessed by measuring iron concentration, glutathione peroxidase 4 (Gpx4) and Prostaglandin endoperoxide synthase 2 (Ptgs2) expression, glutathione (GSH) level, lipid peroxidation, and reactive oxygen species (ROS) level. We found that decursin treatment decreased CCl4-induced liver fibrosis. The primary HSCs isolated from decursin-treated group showed an increased Fe2+, lipid ROS level, and decreased Gpx4 and GSH levels compared with HSCs from model group. Moreover, decursin promoted ferroptosis in activated HSCs in vitro, as evidenced by declined Gpx4 and GSH levels, increased Fe2+, ROS, and Ptgs2 levels compared with control. More important, ferroptosis inhibitor destroyed the anti-fibrosis effect of decursin on HSCs. In summary, these data suggest that decursin has potential to treat hepatic fibrosis.
ObjectiveThis study was conducted in order to gain a better understanding of the molecular mechanisms of stomach adenocarcinoma (STAD), which is necessary to predict the prognosis of STAD and develop novel gene therapy strategies.MethodsIn this study, the gene expression profile of GSE118916 in the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Program (TCGA) was used to explore the differential co-expression genes of STAD and normal tissues.ResultsA total of 407 STAD samples were collected, consisting of 375 from stomach adenocarcinoma tissues and 32 from normal tissues, as well as RNA-seq count data for 19,600 genes. Forty-two differentially expressed genes were screened by weighted gene co-expression network analysis (WGCNA) and differentially expressed gene analysis. According to the functional annotation analysis of the clusterProfiler R package, these genes were analyzed for GO function enrichment, digestion (biological process), tube bottom material membrane (cell component), and oxidoreductase activity (molecular function). The KEGG pathway was enriched in gastric acid secretion and chemical carcinogenesis. In addition, Cytoscape’s cytoHubba plug-in was used to identify seven hub genes (EWSR1, ESR1, CLTC, PCMT1, TP53, HUWE1, and HDAC1) in a protein–protein interaction (PPI) network consisting of 7 nodes and 11 edges. Compared with normal tissues, CLTC and TP53 genes were upregulated in stomach adenocarcinoma (P < 0.05). TP53 was expressed differently in stages II and IV, EWSR1 was expressed differently in stages II and III, and ESR1 was expressed differently in stages I–III. Among the seven hub genes, Kaplan–Meier analysis and TCGG showed that the expression levels of HDAC1 and CLTC were significantly correlated with OS in patients with stomach adenocarcinoma (P < 0.05). GEPIA2 analysis showed that ESR1 expression was closely correlated with OS and DFS in gastric adenocarcinoma (P < 0.05). Then, the expression of the genes and their correlations were revealed by the R2 Platform (http://r2.amc.nl). Finally, we collected 18 pairs of gastric mucosal tissues from normal people and cancer tissues from patients with stomach adenocarcinoma. The expression levels of the above seven hub genes and their relative protein expression were detected by RT-PCR and immunohistochemistry (IHC). The results showed that the gene and protein expression levels in stomach adenocarcinoma tissues were increased than those in the normal group.ConclusionIn summary, we believe that the identified hub genes were related to the occurrence of stomach adenocarcinoma, especially the expression of ESR1, HDAC1, and CLTC genes, which are related to the prognosis and overall survival of patients and may become the potential for the future diagnosis and treatment of STAD.
Background: Plasma membrane provides a highly dynamic barriers for cancer cells to interact with their surrounding microenvironment. Membrane tension, a pivotal physical property of plasma membrane, has attracted more and more attention since it plays a role in the progression of various cancers. However, membrane tension related genes (MTRGs) involved in the regulation of colon cancer are not thoroughly understood. This study aimed to identify a prognostic MTRG signature in colon cancer and explore its implications for the disease.Methods: Bulk and Single-cell RNA-seq data and relevant clinical information were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. 44 membrane tension related genes (MTRGs) were obtained through literature. Analysis of differential expressed MTRGs was performed on the RNA-Seq data. By implementing a univariate Cox regression and a LASSO-Cox regression, we developed a prognostic model based on 4 MTRGs. We evaluated the prognostic efficacy of this model using Kaplan–Meier survival curve analysis and receiver operating characteristic (ROC) curve analysis. Moreover, the relationships between this signature and immune cell infiltration, immune status, somatic mutation, pseudo cell differentiation and drug sensitivity were further explored.Results: A 4-MTRG signature was constructed. Risk score derived from the model was further validated as an independent variable for survival prediction. Two risk groups were classified based on the risk score calculated by the 4-MTRG signature. Additionally, we observed a significant difference in immune cells infiltration, such as subsets of CD4 T cells and macrophages, between the high- and low groups. Moreover, in the pseudo-time analysis, TIMP1 was found to express higher as time goes on. Finally, three small molecule drugs, elesclomol, shikonin and bryostatin-1, exhibited binding potential to TIMP-1.Conclusion: The proposed 4-MTRG signature is a promising biomarker to predict clinical outcomes and therapeutic responses in colon cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.